NRX Pharmaceuticals, Inc. reported entering into a Securities Purchase Agreement for a direct offering of 3,959,999 shares at $1.65 per share, with gross proceeds expected to be around $6.5 million, dated August 18, 2025. This is considered a significant event as it affects the company's capital structure.